Alternate
Recent Posts
- Amylyx Secures Funding for Therapy Candidate AMX0035
- The Many Challenges of Getting Out
- Trial of WVE-004 in Patients With C9orf72 Mutations Begins Dosing
- Sperogenix Acquires Rights in China to Develop ABSK021
- Partnership Aims to Lower Out-of-Pocket Costs for Rare Disease Meds
- Masitinib, Given Early in ALS Course, Extends Life, Trial Data Show
- Enrollment in Phase 3 Masitinib Trial Expected to Soon Resume in France
- ALS Association, ‘Stronger as One,’ Adopts Unified Structure
- Nominations Open for 2022 Eurordis Black Pearl Awards
- Time Travel With ALS: What If We Could?